These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

846 related articles for article (PubMed ID: 17470851)

  • 1. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.
    Kuebler JP; Wieand HS; O'Connell MJ; Smith RE; Colangelo LH; Yothers G; Petrelli NJ; Findlay MP; Seay TE; Atkins JN; Zapas JL; Goodwin JW; Fehrenbacher L; Ramanathan RK; Conley BA; Flynn PJ; Soori G; Colman LK; Levine EA; Lanier KS; Wolmark N
    J Clin Oncol; 2007 Jun; 25(16):2198-204. PubMed ID: 17470851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses.
    Yothers G; O'Connell MJ; Allegra CJ; Kuebler JP; Colangelo LH; Petrelli NJ; Wolmark N
    J Clin Oncol; 2011 Oct; 29(28):3768-74. PubMed ID: 21859995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07.
    Land SR; Kopec JA; Cecchini RS; Ganz PA; Wieand HS; Colangelo LH; Murphy K; Kuebler JP; Seay TE; Needles BM; Bearden JD; Colman LK; Lanier KS; Pajon ER; Cella D; Smith RE; O'Connell MJ; Costantino JP; Wolmark N
    J Clin Oncol; 2007 Jun; 25(16):2205-11. PubMed ID: 17470850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
    André T; Boni C; Navarro M; Tabernero J; Hickish T; Topham C; Bonetti A; Clingan P; Bridgewater J; Rivera F; de Gramont A
    J Clin Oncol; 2009 Jul; 27(19):3109-16. PubMed ID: 19451431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis.
    Kuebler JP; Colangelo L; O'Connell MJ; Smith RE; Yothers G; Begovic M; Robinson B; Seay TE; Wolmark N
    Cancer; 2007 Nov; 110(9):1945-50. PubMed ID: 17853393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The toxicity and efficacy of Nordic-FLOX regimen as adjuvant treatment of stage III colon cancer.
    Demir L; Somali I; Oktay Tarhan M; Erten C; Ellidokuz H; Can A; Dirican A; Vedat Bayoglu I
    J BUON; 2011; 16(4):682-8. PubMed ID: 22331722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
    de Gramont A; Van Cutsem E; Schmoll HJ; Tabernero J; Clarke S; Moore MJ; Cunningham D; Cartwright TH; Hecht JR; Rivera F; Im SA; Bodoky G; Salazar R; Maindrault-Goebel F; Shacham-Shmueli E; Bajetta E; Makrutzki M; Shang A; André T; Hoff PM
    Lancet Oncol; 2012 Dec; 13(12):1225-33. PubMed ID: 23168362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study.
    Papadimitriou CA; Papakostas P; Karina M; Malettou L; Dimopoulos MA; Pentheroudakis G; Samantas E; Bamias A; Miliaras D; Basdanis G; Xiros N; Klouvas G; Bafaloukos D; Kafiri G; Papaspirou I; Pectasides D; Karanikiotis C; Economopoulos T; Efstratiou I; Korantzis I; Pisanidis N; Makatsoris T; Matsiakou F; Aravantinos G; Kalofonos HP; Fountzilas G
    BMC Med; 2011 Jan; 9():10. PubMed ID: 21281463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.
    Haller DG; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Gilberg F; Rittweger K; Schmoll HJ
    J Clin Oncol; 2011 Apr; 29(11):1465-71. PubMed ID: 21383294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial.
    Andre T; Colin P; Louvet C; Gamelin E; Bouche O; Achille E; Colbert N; Boaziz C; Piedbois P; Tubiana-Mathieu N; Boutan-Laroze A; Flesch M; Buyse M; de Gramont A
    J Clin Oncol; 2003 Aug; 21(15):2896-903. PubMed ID: 12885807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
    André T; Boni C; Mounedji-Boudiaf L; Navarro M; Tabernero J; Hickish T; Topham C; Zaninelli M; Clingan P; Bridgewater J; Tabah-Fisch I; de Gramont A;
    N Engl J Med; 2004 Jun; 350(23):2343-51. PubMed ID: 15175436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
    Schmoll HJ; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Hoersch S; Rittweger K; Haller DG
    J Clin Oncol; 2015 Nov; 33(32):3733-40. PubMed ID: 26324362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
    André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
    J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
    Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
    Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is oxaliplatin combined with weekly bolus 5-fluorouracil and leucovorin an option for stage II and III colon cancer?
    Twelves C
    Nat Clin Pract Oncol; 2008 Feb; 5(2):72-3. PubMed ID: 18030299
    [No Abstract]   [Full Text] [Related]  

  • 16. FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer.
    Sharif S; O'Connell MJ; Yothers G; Lopa S; Wolmark N
    Cancer Invest; 2008 Nov; 26(9):956-63. PubMed ID: 18798075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.
    Schmoll HJ; Cartwright T; Tabernero J; Nowacki MP; Figer A; Maroun J; Price T; Lim R; Van Cutsem E; Park YS; McKendrick J; Topham C; Soler-Gonzalez G; de Braud F; Hill M; Sirzén F; Haller DG
    J Clin Oncol; 2007 Jan; 25(1):102-9. PubMed ID: 17194911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.
    Lembersky BC; Wieand HS; Petrelli NJ; O'Connell MJ; Colangelo LH; Smith RE; Seay TE; Giguere JK; Marshall ME; Jacobs AD; Colman LK; Soran A; Yothers G; Wolmark N
    J Clin Oncol; 2006 May; 24(13):2059-64. PubMed ID: 16648506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer.
    Allegra CJ; Yothers G; O'Connell MJ; Sharif S; Colangelo LH; Lopa SH; Petrelli NJ; Goldberg RM; Atkins JN; Seay TE; Fehrenbacher L; O'Reilly S; Chu L; Azar CA; Wolmark N
    J Clin Oncol; 2009 Jul; 27(20):3385-90. PubMed ID: 19414665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer.
    Chen L; Wang Y; Cai C; Ding Y; Kim RS; Lipchik C; Gavin PG; Yothers G; Allegra CJ; Petrelli NJ; Suga JM; Hopkins JO; Saito NG; Evans T; Jujjavarapu S; Wolmark N; Lucas PC; Paik S; Sun M; Pogue-Geile KL; Lu X
    J Clin Oncol; 2024 May; 42(13):1520-1530. PubMed ID: 38315963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.